References

US Preventive Services Task Force. Grade definitions. Accessed 17 Jul 2024.

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024 (Apr 4).

doi: 10.3322/caac.21834. Online ahead of print.

American Cancer Society (ACS). Facts and Figures 2024. Accessed 11 Mar 2024.

Health at a Glance: Europe 2020. State of Health in the EU Cycle. Cancer Incidence and Mortality. Accessed 11 Mar 2024.

World Health Organization (WHO). International Agency for Research on Cancer. Cancer Today. Accessed 11 Mar 2024.

van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 2016;51(6):1070-1090, e1079.

Paice JA, Von Roenn JH. Under- or overtreatment of pain in the patient with cancer: how to achieve proper balance. J Clin Oncol2014;32(16):1721–1726.

Deandrea S, Montanari M, Moja L, Apolone G (2008) Prevalence of undertreatment in cancer

A review of published literature. Ann Oncol 2008;19(12):1985–1991.

Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(27):3325-3345.

American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2022-2024. Atlanta: American Cancer Society; 2022. Accessed 11 Mar 2024.

Jiang C, Wang H, Wang Q, Luo Y, Sidlow R, Han X. Prevalence of chronic pain and high-impact chronic pain in cancer survivors in the United States. JAMA Oncol 2019;5(8):1224-1226.

Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002;20(19):4040-4049.

Rauck RL, Wallace MS, Leong MS. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006;31(5):393-406.

Brogan SE, Winter NB, Okifuji A. Prospective observational study of patient-controlled intrathecal analgesia: impact on cancer-associated symptoms, breakthrough pain control, and patient satisfaction. Reg Anesth Pain Med 2015;40(4):369-375.

Carvajal G, Dupoiron D, Seegers V, et al. Intrathecal drug delivery systems for refractory pancreatic cancer pain: observational follow-up study over an 11-year period in a comprehensive cancer center. Anesth Analg 2018;126(6):2038-2046.

Stearns LJ, Narang S, Albright AE, et al. Assessment of health care utilization and cost of targeted drug delivery and conventional medical management vs conventional medical management alone for patients with cancer-related pain. JAMA Netw Open 2019;2(4):e191549.

Ma K, Jin Y, Wang L, et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain 2020;161(11):2502-2510.

Sindt JE, Odell DW, Dalley AP, Brogan SE. Initiation of intrathecal drug delivery dramatically reduces systemic opioid use in patients with advanced cancer. Neuromodulation 2020 Oct 27;23(7):978–983.

Brogan SE, Sindt JE, Jackman CE, White J, Wilding V, Okifuji A. Prospective association of serum opioid levels and clinical outcomes in patients with cancer pain treated with intrathecal opioid therapy. Anesth Analg 2020;130(4):1035-1044.

Goel V, Kumar V, Blaes A, Gulati A. Intrathecal drug delivery systems for cancer pain control: insights on current contemporary practices in the US. Neuromodulation 2023 Aug;26(6):1256-1262. doi: 10.1016/j.neurom.2023.05.001. Epub 2023 Jun 15. PMID: 37318432.

Pope JE, Deer TR, Bruel BM, Falowski S. Clinical uses of intrathecal therapy and its placement in the pain care algorithm. Pain Pract 2016 Nov;16(8):1092-1106. doi: 10.1111/papr.12438. Epub 2016 Feb 23. PMID: 26914961.

Deer T, Winkelmüller W, Erdine S, Bedder M, Burchiel K. Intrathecal therapy for cancer and nonmalignant pain: patient selection and patient management. Neuromodulation 1999;2(2):55-66.

Maron J, Loeser JD. Spinal opioid infusions in the treatment of chronic pain of nonmalignant origin. Clin J Pain 1996;12(3):174-179.

Deer TR, Smith HS, Burton AW, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician 2011;14(3):E283-312.

Ahmed SU, Martin NM, Chang Y. Patient selection and trial methods for intraspinal drug delivery for chronic pain: a national survey. Neuromodulation 2005;8(2):112-120.

Capozza MA, Triarico S, Mastrangelo S, Attina G, Maurizi P, Ruggiero A. Narrative review of intrathecal drug delivery (IDD): indications, devices and potential complications. Ann Transl Med 2021;9(2):186.

Deer TR, Pope JE, Hanes MC, McDowell GC. Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options. Pain Med 2019;20(4):784-798.

Staudt MD, Prabhala T, Sheldon BL, et al. Current strategies for the management of painful diabetic neuropathy. J Diabetes Sci Technol 2020:1932296820951829.

Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks. Neuromodulation 2017;20:155-176.

Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation 2017;20(2):96-132.

Deer TR, Smith HS, Cousins M, et al. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician 2010;13,3:E175-213.

Staats PS, Yearwood T, Charapata SJ, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004;291(1):63-70.,

Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg 2008;106(3):685-712.

Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009;53(23):2129-2140.

Filos KS, Goudas LC, Patroni O, Polyzou V. Hemodynamic and analgesic profile after intrathecal clonidine in humans. a dose-response study. Anesthesiology 1994;81(3):591-601; discussion 27A-28A.

Kroin JS, McCarthy RJ, Penn RD, Lubenow TJ, Ivankovich AD. Continuous intrathecal clonidine and tizanidine in conscious dogs: analgesic and hemodynamic effects. Anesth Analg 2003;96(3):776-782.

Engelman E, Marsala C. Efficacy of adding clonidine to intrathecal morphine in acute postoperative pain: meta-analysis. Br J Anaesth 2013;110(1):21-27.

Lee HM, Ruggoo V, Graudins A. Intrathecal clonidine pump failure causing acute withdrawal syndrome with ‘stress-induced’ cardiomyopathy. J Med Toxicol 2016;12(1):134-138.

Twiddy H, Frank B, Alam U. A consideration of the psychological aspects to managing patients with painful diabetic neuropathy: an insight into pain management services at a tertiary centre in the UK. Diabetes Ther 12021;2(2):487-498.

Greenhalgh DG. Wound healing and diabetes mellitus. Clin Plast Surg 2003;30(1):37-45.

Follett KA, Boortz-Marx RL, Drake JM, et al. Prevention and management of intrathecal drug delivery and spinal cord stimulation system infections. Anesthesiology 2004;100(6):1582-1594.

Van den Berghe G. How does blood glucose control with insulin save lives in intensive care?” J Clin Invest 2004;114(9):1187-1195.

Duarte RV, Raphael JH, Labib M, Southall JL, Ashford RL. Prevalence and influence of diagnostic criteria in the assessment of hypogonadism in intrathecal opioid therapy patients. Pain Physician 2013;16(1):9-14.

Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000;16(3):251-254.

Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000;85(6):2215-2222.

Roberts LJ, Finch PM, Pullan PT, Bhagat CI, Price LM. Sex hormone suppression by intrathecal opioids: a prospective study. Clin J Pain 2002;18(3):144-148.

Valverde-Filho J, da Cunha Neto MB, Fonoff ET, Meirelles Ede S, Teixeira MJ. Chronic spinal and oral morphine-induced neuroendocrine and metabolic changes in noncancer pain patients. Pain Med 2015;16(4):715-725.

Kim CH, Garcia R, Stover J, Ritchie K, Whealton T, Ata MA. Androgen deficiency in long-term intrathecal opioid administration. Pain Physician 2014;17(4):E543-548.

Deer TR, Narouze S, Provenzano DA, et al. The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations on bleeding and coagulation management in neurostimulation devices. Neuromodulation 2017;20(1):51-62.

Abd-Elsayed A, Karri J, Michael A, et al. Intrathecal drug delivery for chronic pain syndromes: a review of considerations in practice management. Pain Physician 2020;23(6): E591-E617.

Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the Second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003;28(3):172-197.

Spyropoulos AC, Brohi K, Caprini J, Samama CM, Siegal D, Tafur A, Verhamme P, Douketis JD; SSC Subcommittee on Perioperative and Critical Care Thrombosis and Haemostasis of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. J Thromb Haemost 2019 Nov;17(11):1966-1972. doi: 10.1111/jth.14598. Epub 2019 Aug 22. PMID: 31436045.

Douketis JD, Healey JS, Brueckmann M, e al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost 2015 Mar;113(3):625-32. doi: 10.1160/TH14-04-0305. Epub 2014 Dec 4. PMID: 25472710.

Marquez J, Togami JC, Dant CR, Herrera A, Marshik P, Burnett AE. Peri-procedural antithrombotic management: time to burn the bridge? J Thromb Thrombolysis 2018 Apr;45(3):337-344. doi: 10.1007/s11239-018-1616-3. PMID: 29383558.

Sindt JE, Fitzgerald LA, Kuznicki J, Prelewicz S, Odell DW, Brogan SE. Antiplatelet and wound healing implications of immunotherapy and targeted cancer therapies in the perioperative period. Anesthesiology 2023;139(4):511-522.

Knight KH, Brand FM, McHaourab MS, Veneziano G. Implantable intrathecal pumps for chronic pain: highlights and updates. Croat Med J 2007;48(1):22-34.

Deer TR, Provenzano DA, Hanes M, et al. The Neurostimulation Appropriateness Consensus Committee (NACC) Recommendations for infection prevention and management. Neuromodulation 2017;20(1):31-50.

Di Bari M, Virgillo A, Matteuzzi D, et al. Predictive validity of measures of comorbidity in older community dwellers: The Insufficienza Cardiaca Negli Anziani Residenti a Dicomano Study. J Am Geriatr Soc 2006;54(2):210-216.

Rozzini R, Frisoni GB, Ferrucci L, et al. Geriatric index of comorbidity: validation and comparison with other measures of comorbidity. Age Ageing 2002;31(4):277-285.

Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: Consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step iii opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8(4):287-313.

Buntin-Mushock C, Phillip L, Moriyama K, Palmer PP. Age-dependent opioid escalation in chronic pain patients. Anesth Analg2005;100(6):1740-1745.

Dominguez E, Sahinler B, Bassam D, Day M, Lou L, Racz G, et al. Predictive value of intrathecal narcotic trials for long-term therapy with implantable drug administration systems in chronic non-cancer pain patients. Pain Practice 2002;2(4):315-325.

Hayek SM, Veizi IE, Narouze SN, Mekhail N. Age-dependent intrathecal opioid escalation in chronic noncancer pain patients. Pain Med 2011;12(8):1179-1189.

Kim D, Saidov A, Mandhare V, Shuster A. Role of pretrial systemic opioid requirements, intrathecal trial dose, and non-psychological factors as predictors of outcome for intrathecal pump therapy: one clinician’s experience with lumbar postlaminectomy pain. Neuromodulation 2011;14(2):165-175; discussion 75.

Prager J, Deer T, Levy R, et al. Best practices for intrathecal drug delivery for pain. Neuromodulation 2014;17(4):354-372; discussion 372.

Gorlin AW, Rosenfeld DM, Maloney J, Wie CS, McGarvey J, Trentman TL. Survey of pain specialists regarding conversion of high-dose intravenous to neuraxial opioids. J Pain Res 2016;9:693-700.

Sukul VV. Intrathecal pain therapy for the management of chronic noncancer pain. Neurosurg Clin N Am 2019;30(2):195-201.

Cummings A, Orgill BD, Fitzgerald BM. Intrathecal morphine. In: Treasure Island (FL); 2020.

Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002;18(4 Suppl):S3-13.

Yaksh TL, Fisher CJ, Hockman TM, Wiese AJ. Current and future issues in the development of spinal agents for the management of pain. Curr Neuropharmacol 2017;15(2):232-259. doi: 10.2174/1570159×14666160307145542. PMID: 26861470; PMCID: PMC5412694

Yaksh TL, Santos GGD, Borges Paes Lemes J, Malange K. Neuraxial drug delivery in pain management: An overview of past, present, and future. Best Pract Res Clin Anaesthesiol 2023 Jun;37(2):243-265. doi: 10.1016/j.bpa.2023.04.003. Epub 2023 Apr 14. PMID: 37321769

Yaksh TL, Allen JW, Veesart SL, et al. Role of meningeal mast cells in intrathecal morphine-evoked granuloma formation. Anesthesiology 2013;118(3):664-678.

Allen JW, Horais KA, Tozier NA, Yaksh TL. Opiate pharmacology of intrathecal granulomas. Anesthesiology 2006;105(3):590-598.

Michael A, Buffen E, Rauck R, Anderson W, McGirt M, Mendenhall HV. An in vivo canine study to assess granulomatous responses in the MedStream Programmable Infusion System (TM) and the SynchroMed II Infusion System(R). Pain Med 2012;13(2):175-184.

Gradert TL, Baze WB, Satterfield WC, Hildebrand KR, Johansen MJ, Hassenbusch SJ. Safety of chronic intrathecal morphine infusion in a sheep model. Anesthesiology 2003;99(1):188-198.

Bolon B, Butt MT. Fundamental neuropathology for pathologists and toxicologists : principles and techniques. Hoboken, NJ: Wiley; 2011.

Yaksh TL, Eddinger KA, Kokubu S, et al. Mast cell degranulation and fibroblast activation in the morphine-induced spinal mass: role of mas-related G protein-coupled receptor signaling. Anesthesiology 2019 Jul;131(1):132-147. doi: 10.1097/ALN.0000000000002730. PMID: 31225809; PMCID: PMC6590697.

Lansu K, Karpiak J, Liu J, Huang XP, McCorvy JD, Kroeze WK, Che T, Nagase H, Carroll FI, Jin J, Shoichet BK, Roth BL. In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nat Chem Biol 2017; 13: 529–536 .

Zhang T, Liu R, Che D, et al. A mast cell-specific receptor is critical for granuloma induced by intrathecal morphine infusion. J Immunol 2019;203(7):1701-1714.

Pisansky AJB, MacDougall BJ, Ross EL, Chi JH, Neville G, Yaksh TL. Catheter tip-associated mass with continuous infusion of sufentanil for persistent spinal pain syndrome Type 2: a case report including histopathologic examination and review of the associated basic and clinical research. Neuromodulation 2024 Mar 5:S1094-7159(24)00031-X. doi: 10.1016/j.neurom.2023.12.008. Epub ahead of print. PMID: 38441505

Bschorer M, Martinez-Moreno M, Tietke M, Heese O. The management of unresectable intrathecal catheter-tip-associated granuloma using morphine therapy cessation and spinal cord stimulation. Cureus 2020;12(8):e10160.

Gui M, Sehgal N. Symptomatic intrathecal catheter tip granuloma formation with ultralow-dose and low-concentration morphine infusion: a case report and review of literature. Neuromodulation 2023;26(6):1164-1170.

Veizi IE, Hayek SM, Hanes M, Galica R, Katta S, Yaksh T. Primary hydromorphone-related intrathecal catheter tip granulomas: is there a role for dose and concentration? Neuromodulation 2016 Oct;19(7):760-769.

Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012;15(5):436-464; discussion 464-436.

Mastenbroek TC, Kramp-Hendriks BJ, Kallewaard JW, Vonk JM. Multimodal intrathecal analgesia in refractory cancer pain. Scand J Pain 2017 Jan;14:39-43. doi: 10.1016/j.sjpain.2016.10.002. Epub 2016 Nov 1. PMID: 28850428.

Kumar P, Sunkaraneni S, Sirohi S, Dighe SV, Walker EA, Yoburn BC. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation. Eur J Pharmacol 2008;597(1-3):39-45.

Johansen MJ, Satterfield WC, Baze WB, Hildebrand KR, Gradert TL, Hassenbusch SJ. Continuous intrathecal infusion of hydromorphone: safety in the sheep model and clinical implications. Pain Med 2004;5(1):14-25.

Zacest AC, Carlson JD, Nemecek A, Burchiel KJ. Surgical management of spinal catheter granulomas: operative nuances and review of the surgical literature. Neurosurgery 2009 Dec;65(6):1161-4; discussion 1164-5. doi: 10.1227/01.NEU.0000359223.11215.D9. PMID: 19934976

Southwell DG, Osorio JA, Liverman CS, Friedman LM, Naidu RK, Poree LR, Henry MM, Jacques L. Intrathecal catheter-associated inflammatory mass in a neurofibromatosis type-1 patient receiving fentanyl and bupivacaine. Surg Neurol Int 2017 Jul 25;8:159. doi: 10.4103/sni.sni_80_17. PMID: 28808608; PMCID: PMC5535511

Ade T, Roh J, Sharma G, et al. Comparative effectiveness of targeted intrathecal drug delivery using a combination of bupivacaine with either low-dose fentanyl or hydromorphone in chronic back pain patients with lumbar postlaminectomy syndrome. Pain Med 2020;21(9):1921-1928.

Gupta A, Martindale T, Christo PJ. Intrathecal catheter granuloma associated with continuous sufentanil infusion. Pain Med2010 Jun;11(6):847-52. doi: 10.1111/j.1526-4637.2010.00860.x. Epub 2010 Apr 29. PMID: 20456073

Warner L, Branstad A, Hunter Guevara L, et al. Malfunctioning sufentanil intrathecal pain pump: a case report. J Med Case Rep 2020;14(1):1.

Jain S, Malinowski M, Chopra P, Varshney V, Deer TR. Intrathecal drug delivery for pain management: recent advances and future developments. Expert Opin Drug Del 2019;16(8):815-822.

Deer TR, Malinowski M, Varshney V, Pope J. Choice of intrathecal drug in the treatment of neuropathic pain – new research and opinion. Expert Rev Clin Pharmacol 2019;12(10):1003-1007.

Butterworth J, Strichartz G. Molecular mechanisms of local anesthesia: a review. Anesthesiology [Internet] 1990;72:711–34.

McDougall JJ, O’Brien MS. Analgesic potential of voltage gated sodium channel modulators for the management of pain. Curr Opin Pharmacol 2024 Apr;75:102433. doi: 10.1016/j.coph.2024.102433. Epub 2024 Jan 25. PMID: 38277942

Paganelli MA, Popescu GK. Actions of bupivacaine, a widely used local anesthetic, on NMDA receptor responses. J Neurosci 2015 Jan 14;35(2):831-42. doi: 10.1523/JNEUROSCI.3578-14.2015. PMID: 25589775; PMCID: PMC4293426

Huang M, Dalm B, Simpson RK. Toxic myelitis and arachnoiditis after intrathecal delivery of bupivacaine via an implanted drug delivery system: case report and review of the literature. Cureus 2018;10(2):e2240.

Perren F, Buchser E, Chédel D, Hirt L, Maeder P, Vingerhoets F. Spinal cord lesion after long-term intrathecal clonidine and bupivacaine treatment for the management of intractable pain. Pain 2004;109(1-2):189-194.

Spiegel MA, Chen GH, Solla AC, Hingula LP, Legler A, Gulati A. Evaluation of an intrathecal drug delivery protocol leads to rapid reduction of systemic opioids in the oncological population. J Palliat Med 2020;24(3):418–422.

Bottros MM, Christo PJ. Current perspectives on intrathecal drug delivery. J Pain Res 2014;7:615-626.

Sabbe MB, Grafe MR, Pfeifer BL, Mirzai TH, Yaksh TL. Toxicology of baclofen continuously infused into the spinal intrathecal space of the dog. Neurotoxicology 1993 Winter;14(4):397-410. PMID: 8164885

Deer TR, Raso LJ, Garten TG. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication. Pain Med 2007 Apr;8(3):259-62. doi: 10.1111/j.1526-4637.2006.00150.x. PMID: 17371413

Ross JC, Cook AM, Stewart GL, Fahy BG. Acute intrathecal baclofen withdrawal: a brief review of treatment options. Neurocrit Care 2011;14(1):103-108.

Coffey RJ, Ridgely PM. Abrupt intrathecal baclofen withdrawal: management of potentially life-threatening sequelae. Neuromodulation 2001;4(4):142-146.

Bellinger A, Siriwetchadarak R, Rosenquist R, Greenlee JD. Prevention of intrathecal baclofen withdrawal syndrome: successful use of a temporary intrathecal catheter. Reg Anesth Pain Med 2009;34(6):600-602.

Duhon BS, MacDonald JD. Infusion of intrathecal baclofen for acute withdrawal. Technical note. J Neurosurg 2007;107(4):878-880.

Watve SV, Sivan M, Raza WA, Jamil FF. Management of acute overdose or withdrawal state in intrathecal baclofen therapy. Spinal Cord 2021;50(2):107-111.

Saulino M, Anderson DJ, Doble J, Farid R, Gul F, Konrad P, Boster AL. Best practices for intrathecal baclofen therapy: troubleshooting. Neuromodulation 2016;19(6):632-641.

Meulendijks D, Khan S, Koks CH, Huitema AD, Schellens J H, Beijnen JH. Baclofen overdose treated with continuous venovenous hemofiltration. Eur J Clin Pharmacol 2015;71(3):357-361.

Müller-Schwefe G, Penn RD. Physostigmine in the treatment of intrathecal baclofen overdose: report of three cases. J Neurosurg 1989 Aug 1;71(2):273-275.

Murphy PM, Skouvaklis DE, Amadeo RJ, Haberman C, Brazier DH, Cousins MJ. Intrathecal catheter granuloma associated with isolated baclofen infusion. Anesth Analg 2006;102(3):848-852. doi:10.1213/01.ane.0000196523.06573.10

Creamer M, Cloud G, Kossmehl P, et al. Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). J Neurol Neurosurg Psychiatry 2018;89(6):642-650.

Kumar A, Maitra S, Khanna P, Baidya DK. Clonidine for management of chronic pain: A brief review of the current evidences. Saudi J Anaesth 2014;8(1):92-96. doi:10.4103/1658-354X.125955

Yaksh TL. Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing. Pharmacol Biochem Behav 1985;22:845–858.

Gordh T, Jr, Jansson I, Hartvig P, et al. Interactions between noradrenergic and cholinergic mechanisms involved in spinal nociceptive processing. Acta Anaesthesiol Scand 1989;33:39–47. doi: 10.1111/j.1399-6576.1989.tb02857.x

Gaumann DM, Brunet PC, Jirounek P. Clonidine enhances the effects of lidocaine on C-fiber action potential. Anesth Analg1992;74:719–25. doi: 10.1213/00000539-199205000-00017

Hassenbusch SJ, Gunes S, Wachsman S, Willis D. Intrathecal clonidine in the treatment of intractable pain: a phase I/II study. Pain Med 2002;3(2):85–91.

Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 2003;26:668–677.

Siddall PJ, Molloy AR, Walker S, Mather LE, Rutkowski SB, Cousins MJ. The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg 2000;91(6):1493-1498. doi:10.1097/00000539-200012000-00037

Rudich Z, Peng P, Dunn E, McCartney C. Stability of clonidine in clonidine-hydromorphone mixture from implanted intrathecal infusion pumps in chronic pain patients. J Pain Symptom Manage 2004;28(6):599-602. doi:10.1016/j.jpainsymman.2004.02.018

Wong AC, Hayek SM. Intrathecal drug delivery: medication selection. In: Diwan S, Deer T, (eds). Advanced Procedures for Pain Management. Springer, Cham; 2018. Accessed Feb 21, 2022.

Brogan SE, Sindt JE, Odell DW, Gulati A, Dupoiron D. Controversies in intrathecal drug delivery for cancer pain. Region Anesth Pain Med 2023;48(6):319-325.

Pope JE, Deer TR, Amirdelfan K, McRoberts WP, Azeem N. The pharmacology of spinal opioids and ziconotide for the treatment of non-cancer pain. Curr Neuropharmacol 2017;15(2):206–216.

Safavi-Hemami H, Brogan SE, Olivera BM. Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways. J Proteomics 2019;190:12-20.

Skov MJ, Beck JC, de Kater AW, Shopp GM. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Int J Toxicol 2007;26(5):411-421. doi:10.1080/10915810701582970

Webster LR. The relationship between the mechanisms of action and safety profiles of intrathecal morphine and ziconotide: A review of the literature. Pain Med 2015;16(7):1265–77.

Deer T, Hagedorn JM. How has ziconotide impacted non-cancer pain management? Expert Opin Pharmacother2020;21(5):507-511.

Deer T, Rauck RL, Kim P, et al. Effectiveness and safety of intrathecal ziconotide: Interim analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Pract 2018;18(2):230–238.

Prusik J, Argoff C, Peng S, Pilitsis JG. Use of low dose ziconotide as first-line intrathecal monotherapy. Neuromodulation 2017;20(4):386-391.

Deer TR, Kim C, Bowman R, Tolentino D, Stewart C, Tolentino W. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study. Pain Physician 2009;12(4):E291-E296.

Staats PS, Luthardt F, Shipley J, Jackson C, Fischer K. Long-term intrathecal ziconotide therapy: a case study and discussion. Neuromodulation 2001;4(3):121-126.

McDowell G, Saulino MF, Wallace M, et al. Effectiveness and safety of intrathecal ziconotide: final results of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Med 2020;21(11):2925–2938.

Product Performance Report. Summary of Data from the Medtronic Post-Market Registry 2022. v 1.0, 05 May 2023. Accessed 12 Mar 2024.

Wang YX, Gao D, Pettus M, Phillips C, Bowersox SS. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 2000;84(2-3):271-281.

Alicino I, Giglio M, Manca F, Bruno F, Puntillo F. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain 2012;153(1):245-249.

Sindt JE, Odell DW, Tariq R, Presson AP, Zhang C, Brogan SE. Initial intrathecal dose titration and predictors of early dose escalation in patients with cancer using a 100:1 oral to intrathecal morphine conversion ratio. Neuromodulation 2021;24(7):1157-1166.

United States Pharmacopiea (USP). Updates to USP general chapters <795> and <797>, Nov. 1, 2022. Accessed 23 Feb 2024.

Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect 2013;14(1):73-156.

de Lange MP, Sonker U, Kelder JC, de Vos R. Practice variation in treatment of suspected asymptomatic bacteriuria prior to cardiac surgery: are there differences in postoperative outcome? A retrospective cohort study. Interactive Cardiovasc Thor Surg 2016;22(6):769-775.

Sendi P, Borens O, Wahl P, Clauss M, Uckay I. Management of asymptomatic bacteriuria, urinary catheters and symptomatic urinary tract infections in patients undergoing surgery for joint replacement: a position paper of the expert group ‘Infection’ of Swiss orthopaedics. J Bone Joint Infect 2017;2(3):154-159.

Patel S, Hafez O, Sexton WJ, Edwards DA. Perioperative management of a patient with an intrathecal drug delivery device infusing ziconotide: a case report. A & A Case Rep 2017;8(4):78-80.

Grider JS, Brown RE, Colclough GW. Perioperative management of patients with an intrathecal drug delivery system for chronic pain. Anesth Analg 2008;107(4):1393-1396.

Balaratnam MS, Donnelly A, Padilla H, et al. Reducing Intrathecal baclofen related infections: service evaluation and best practice guidelines. Neuromodulation 2020;23(7):991-995.

Apfelbaum JL, Silverstein JH, Chung FF, et al. Practice guidelines for postanesthetic care: an updated report by the American Society of Anesthesiologists Task Force on Postanesthetic Care. Anesthesiology 2013;118(2):291-307.

Ali ZS, Flanders TM, Ozturk AK, et al. Enhanced recovery after elective spinal and peripheral nerve surgery: pilot study from a single institution. J Neurosurg Spine 2019:1-9.

Neuman SA, Eldrige JS, Qu W, Freeman ED, Hoelzer BC. Post dural puncture headache following intrathecal drug delivery system placement. Pain Physician 2013;16(2):101-107.

Miracle AC, Fox MA, Ayyangar RN, Vyas A, Mukherji SK, Quint DJ. Imaging evaluation of intrathecal baclofen pump-catheter systems. AJNR 2011;32(7):1158-1164.

Ihemelandu CU, McQuellon R, Shen P, Stewart JH, Votanopoulos K, Levine EA. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ann Surg Oncol 2013;20(11):3519-3526.

Glance LG, Blumberg N, Eaton MP, et al. Preoperative thrombocytopenia and postoperative outcomes after noncardiac surgery. Anesthesiology 2014;120(1):62-75.

Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. Br J Haematol 2017;176(3):365-394.

Bamba R, Lorenz JM, Lale AJ, Funaki BS, Zangan SM. Clinical predictors of port infections within the first 30 days of placement. J Vasc Interv Radiol 2014;25(3):419-423.

Skummer P, Kobayashi K, DeRaddo JS, Blackburn T, Schoeneck M, Patel J, Jawed M. Risk factors for early port infections in adult oncologic patients. J Vasc Interv Radiol 2020;31(9):1427-1436.

Chen IC, Hsu C, Chen CY, et al. Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients. Ann Oncol 2013;24(2):463-468.

Sindt JE, Larsen SD, Dalley, Collier WH, Brogan SE. The rate of infectious complications after intrathecal drug delivery system implant for cancer-related pain is low despite frequent concurrent anticancer treatment or leukopenia. Anesth Analg2020;131(1):280-287.

Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H. The role of vascular endothelial growth factor in wound healing. J Surg Res 2009;153(2):347-358.

Crist M, Hansen E, Chablani L, Guancial E. Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2017;120:151-162.

Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 2017;15(5):835-847.

Odell DW, Albrechtsen RD, Sindt JE, et al. The effect of measured radiotherapy dose on intrathecal drug delivery system function. Neuromodulation 2021;24(7):1204-1208.

Product Surveillance Registry (PSR) Database. Minneapolis, MN; 2015.

Coffey RJ, Owens ML, Broste SK et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology 2009;111:881–891.

Fitzgibbon DR, Stephens LS, Posner KL, et al. Injury and liability associated with implantable devices for chronic pain. Anesthesiology 2016;124:1384–1393.

Coffey RJ, Owens ML, Broste SK, et al. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain. Pain Med 2010;11:1001–1009.

Shankar H. Ultrasound-guided localization of difficult-to-access refill port of the intrathecal pump reservoir. Neuromodulation2009;12:216-218.

Di Chiro G. Movement of the cerebrospinal fluid in human beings. Nature 1964;204(4955):290-291.

Oreskovic D, Klarica M. The formation of cerebrospinal fluid: nearly a hundred years of interpretations and misinterpretations. Brain Res Rev 2010;64:241-262. doi:10.1016/j.brainresrev.2010.04.006

Bernards CM. In: Yaksh TL, ed. Spinal Drug Delivery. Elsevier; 1999: Ch 9, 239-252.

Artru AA. In: Yaksh TL, ed. Spinal Drug Delivery. Elsevier; 1999: Ch 8, 177-237.

Baledent O, Henry-Feugeas MC, Idy-Peretti I. Cerebrospinal fluid dynamics and relation with blood flow: a magnetic resonance study with semiautomated cerebrospinal fluid segmentation. Invest Radiol 2001;36:368-377.

Henry-Feugeas MC, Idy-Peretti I, Blanchet B, Hassine D, Zannoli G, Schouman-Claeys E. Temporal and spatial assessment of normal cerebrospinal fluid dynamics with MR imaging. Magn Reson Imaging 1993;11:1107-1118.

Flack SH, Bernards CM. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs. Anesthesiology 2010 Jan;112(1):165-173.

Nelissen RM. Fluid Mechanics of Intrathecal Drug Delivery. PhD thesis. Federal Institute of Technology, Lausanne, Switzerland; 2008.

Khani M, Sass LR, Xing T, Keith Sharp M, Balédent O, Martin BA. Anthropomorphic model of intrathecal cerebrospinal fluid dynamics within the spinal subarachnoid space: spinal cord nerve roots increase steady-streaming. J Biomech Eng 2018;140(8):0810121-08101215.

Heidari Pahlavian S, Yiallourou T, Tubbs RS, et al. The impact of spinal cord nerve roots and denticulate ligaments on cerebrospinal fluid dynamics in the cervical spine. PLoS One 2014;9(4):e91888.

Wallace M, Yaksh TL. Characteristics of distribution of morphine and metabolites in cerebrospinal fluid and plasma with chronic intrathecal morphine infusion in humans. Anesth Analg 2012 Oct;115(4):797-804. doi: 10.1213/ANE.0b013e3182645dfd. Epub 2012 Jul 19. PMID: 22822192; PMCID: PMC3456964

Hocking G, Wildsmith JA. Intrathecal drug spread. Br J Anaesth 2004;93:568-578.

Casati A, Fanelli G, Cappelleri G, et al. Does speed of intrathecal injection affect the distribution of 0.5% hyperbaric bupivacaine? Br J Anaesth 1998;81(3):355-357.

Chen GH, Spiegel MA, Magram YC, et al. Evaluation of fixed intrathecal bupivacaine infusion doses in the oncologic population. Neuromodulation 2020;23(7):984-990.

Aman MM, Mahmoud A, Deer T, et al. The American Society of Pain and Neuroscience (ASPN) best practices and guidelines for the interventional management of cancer-associated pain. J Pain Res 2021;14:2139-2164.

Brogan SE, Odell DW, Sindt JE, et al. Dorsal versus ventral intrathecal catheter tip location and effect on dose escalation and opioid use in patients with cancer pain. Neuromodulation 2023;26(6):1233-1239.

Deer TR, Hayek SM, Pope JE, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations for trialing of intrathecal drug delivery infusion therapy. Neuromodulation 2017;20(2):133-154.

Yaksh TL, Kohl RL, Rudy TA. Induction of tolerance and withdrawal in rats receiving morphine in the spinal subarachnoid space. Eur J Pharmacol 1977 Apr 7;42(3):275-284.

Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 1996;11:71-80.

Veizi IE, Hayek SM, Narouze S, Pope JE, Mekhail N. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med 2011;12:1481-1489.

De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991;47(3):337-339.

Singla A, Stojanovic MP, Chen L, Mao J. A differential diagnosis of hyperalgesia, toxicity, and withdrawal from intrathecal morphine infusion. Anesth Analg 2007;105(6):1816-1819.

Aldrete JA, Couto da Silva JM. Leg edema from intrathecal opiate infusions. Eur J Pain 2000;4(4):361-365.

Veizi E, Tornero-Bold M, Hayek SM. Resolution of intrathecal hydromorphone or morphine-induced peripheral edema by opioid rotation to fentanyl: a case series. Pain Practice 2016;16(6):E94-98.

Allen JW, Horais KA, Tozier NA, Wegner K, Corbeil JA, Mattrey RF, et al. Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation. Anesthesiology 2006;105(3):581-589.

Duarte RV, Raphael JH, Southall JL, Baker C, Ashford RL. Intrathecal granuloma formation as result of opioid delivery: systematic literature review of case reports and analysis against a control group. Clin Neurol Neurosurg 2012;114(6):577-584.

Chappel E. Implantable Drug Delivery Devices. In: Chappel E, ed. Drug Delivery Devices and Therapeutic Systems. London: Elsevier Inc.; 2021: 129-156.

Ethans KC, SChryvers OI, Nance PW, Casey AR. Intrathecal drug therapy using the Codman Modell 3000 constant flow implantable infusion pumps: experience with 17 cases. Spinal Cord 2005;43:214-218.

Medtronic PLC. Medtronic SynchroMed® II Infusion System Patient Manual. Minneapolis: Medtronic PLClc: 2017.

Wesemann K, Coffey RJ, Wallace MS, Tan Y, Broste S, Buvanendran A. Clinical accuracy and safety using the SynchroMed II intrathecal drug infusion pump. Reg Anesth Pain Med 2014 Jul-Aug;39(4):341-346.

Farid R, Binz K, Emerson JA, Murdock F. Accuracy and precision of the SynchroMed II Pump. Neuromodulation 2019 Oct;22(7):805-810.

Rauck R, Deer T, Rosen S, Padda G, Barsa J, Dunbar E, Dwarakanath G. Accuracy and efficacy of intrathecal administration of morphine sulfate for treatment of intractable pain using the Prometra(®) Programmable Pump. Neuromodulation 2010 Apr;13(2):102-108.

Rauck R, Deer T, Rosen S, Padda G, Barsa J, Dunbar E, Dwarakanath G. Long-term follow-up of a novel implantable programmable infusion pump. Neuromodulation 2013 Mar-Apr;16(2):163-167.

Dressler D, Berweck S, Chatzikalfas A, et al. Intrathecal baclofen therapy in Germany: Proceedings of the IAB-Interdisciplinary Working Group for Movement Disorders Consensus Meeting. J Neural Transm (Vienna) 2015 Nov;122(11):1573-1579.

Hsu Y, Hettiarachchi HD, Zhu DC, Linninger AA. The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability. Anesth Analg 2012 Aug;115(2):386-394.

Tangen KM, Leval R, Mehta AI, Linninger AA. Computational and in vitro experimental investigation of intrathecal drug distribution: parametric study of the effect of injection volume, cerebrospinal fluid pulsatility, and drug uptake. Anesth Analg 2017 May;124(5):1686-1696.

Hildebrand KR, Page LM, Billstrom TM, Steinauer JJ, Eddinger KA, Arjomand S, Yaksh TL. Characterization of effect of repeated bolus or continuous intrathecal infusion of morphine on spinal mass formation in the dog. Neuromodulation 2019 Oct;22(7):790-798.

Kumru H, Benito-Penalva J, Kofler M, Vidal J. Analgesic effect of intrathecal baclofen bolus on neuropathic pain in spinal cord injury patients. Brain Res Bull 2018;140:205-211.

Buchser E, Durrer A, Chédel D, Mustaki JP. Efficacy of intrathecal bupivacaine: how important is the flow rate? Pai